Anas Younes: How MRD Testing Is Advancing Hematology Care
8h agoen
From the article
Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared a post on LinkedIn: “Conventional response assessments in blood cancer may not fully capture residual disease burden. […]
Continue reading on OncoDailyYou might also wanna read
Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry
clinicaltrials.gov·1d ago
Expert Insights on Achieving Normalization for Hemophilia A Patients
This article features Cedric Hermans, MD, PhD, FRCP, a professor and head of hematology at Saint-Luc University Hospital in Brussels, discus

ASO biotech wants MHRA to go further in new rare disease therapy framework
bioprocessintl.com·26d ago
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
clinicaltrials.gov·7d ago
Mutation-dependent responses to sleep and exercise in clonal haematopoiesis - Nature
nature.com·21d ago
Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol
clinicaltrials.gov·1d ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.